Revance Therapeutics (RVNC) to Offer Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cowen, Piper Jaffray & Co. and Stifel are acting as book-running managers for the proposed offering.

You May Also Be Interested In

• Stifel Upgrades Saia Inc. (SAIA) to Buy, 'Market Focused on the Wrong KPIs'
• DexCom (DXCM) PT Raised to $95 at Stifel
• TriNet Group (TNET) PT Raised to $82 at Stifel